Table 1.
Overview of some of the main CBD molecular targetsa
Molecular targetEffectReferences
CB1 Antagonist, negative allosteric modulator Laprairie et al., 2015; Thomas et al., 2007  
CB2 Antagonist Thomas et al., 2007  
Nav channels Inhibitor Ghovanloo et al., 2018c; Sait et al., 2020  
Kv2.1 channel Inhibitor Ghovanloo et al., 2018c  
Cav channels Inhibitor Deiana et al., 2012; Ross et al., 2008  
TRPV channels Agonist Galaj et al., 2020; Bisogno et al., 2001; Pumroy et al., 2019  
GPR55 Antagonist Harding et al., 2018; Kaplan et al., 2017  
Lipid membrane Decreases elasticity This study 
Molecular targetEffectReferences
CB1 Antagonist, negative allosteric modulator Laprairie et al., 2015; Thomas et al., 2007  
CB2 Antagonist Thomas et al., 2007  
Nav channels Inhibitor Ghovanloo et al., 2018c; Sait et al., 2020  
Kv2.1 channel Inhibitor Ghovanloo et al., 2018c  
Cav channels Inhibitor Deiana et al., 2012; Ross et al., 2008  
TRPV channels Agonist Galaj et al., 2020; Bisogno et al., 2001; Pumroy et al., 2019  
GPR55 Antagonist Harding et al., 2018; Kaplan et al., 2017  
Lipid membrane Decreases elasticity This study 

Cav, voltage-gated calcium channel; GPR55, G protein–coupled receptor 55; Kv2.1, voltage-gated potassium channel; TRPV, transient receptor potential cation channel.

a

See de Almeida and Devi (2020) for a more extensive review of CBD targets and signaling pathways.

or Create an Account

Close Modal
Close Modal